As research has continued, additional treatment options have emerged that may help address the unmet needs of patients with relapsed/refractory multiple myeloma.1 One such option is the combination of Empliciti, an immunotherapy, with pomalidomide and dexamethasone (EPd), which was approved by the U.S. Food & Drug Administration (FDA) in November 2018 for adult patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.3
With this approval, which was based on the randomized Phase 2 ELOQUENT-3 trial, EPd became the first FDA-approved relapsed/refractory triplet regimen with study results versus pomalidomide and dexamethasone (Pd).4,5
Now, additional data from a non-prespecified descriptive analysis of ELOQUENT-3 are available. 6
“The approval of EPd represented an important step forward for appropriate patients with relapsed/refractory multiple myeloma, adding another treatment option in a setting where there is an ongoing need for more therapies,” said Awny Farajallah, M.D., head of U.S. Medical at Bristol-Myers Squibb. “As we see more data from the ELOQUENT-3 trial, we can continue to build on our understanding of the efficacy and safety of the EPd combination over time.”
Empliciti with pomalidomide and dexamethasone is associated with warnings & precautions related to infusions reactions, infections, secondary primary malignancies, hepatotoxicity, interference with determination of complete response, pregnancy/females and males of reproductive potential and adverse reactions. Please see the detailed Important Safety Information at the end of this article.
Data presented at the 24th Congress of the European Hematology Association in Amsterdam, reflect a minimum of 18.3 months of follow-up and include an analysis exploring OS rates for EPd versus Pd alone.6